Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT for C. acnes Decolonization in Shoulder Surgery
NCT04636242Phase 3Unknown
- Sponsor
- Rothman Orthopaedics
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 5-aminolevulinic acid in Cutibacterium acnes colonization and post-operative wound infection (SSI) (2 arms), sponsored by Rothman Orthopaedics. Primary endpoint: Change in C. acnes Microbiological Results at 13 days. Status: unknown.
02
Drugs
5-aminolevulinic acid
03
Conditions
Cutibacterium acnes colonizationpost-operative wound infection (SSI)
Beyond the preview
Go deeper on NCT04636242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636242.